ClinicalTrials.gg
RecruitingNCT07307586Updated Dec 29, 2025

A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B

A Phase 3 interventional study of AZVUDINE and TAF in Chronic Hepatitis B and Azvudine, sponsored by Zhigang Ren. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Zhigang Ren · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Sep 2025, registered Dec 2025).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 378 studies in Hepatitis B, Chronic with a site in China — 91 open to participants now, 112 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
136th of 274
120 · median 120
Started
2025
with 23 others
Phase 3
26 of 378
5 open now
Primary completion
2026-12
later than 41 of 111 live
Registered
342nd of 378
by date

Among the 378 studies in Hepatitis B, Chronic with a site in China, this one is the 136th largest by planned enrollment of the 274 interventional ones that give a count, is one of 24 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 41 of the 111 other live ones, and was the 342nd registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

91 of the 378 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 378 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

Through regular monitoring of viral load, liver function and immune cell activity, the long-term efficacy of Adefovir in controlling HBV is precisely evaluated. By employing a dual mechanism of "antiviral action plus immune activation", it offers a novel therapeutic option for achieving clinical cure in chronic hepatitis B.

03

Conditions studied

  • Chronic Hepatitis B
  • Azvudine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All subjects must meet the following criteria to be eligible for inclusion in the trial:

    1. Meet the diagnostic criteria for viral hepatitis as outlined in the Chinese Medical Association's Hepatology Branch Guidelines for the Prevention and Treatment of Chronic , with patients demonstrating sustained positivity for hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) for at least six months;
    2. HBV DNA load > 20,000 copies/mL and HBsAg \< 1,500 IU/mL;
    3. Serum (ALT) > 2 times the ;
    4. No prior antiviral therapy prior to hospital admission.

Exclusion criteria

Exclusion Criteria:

  • All subjects meeting any of the following criteria shall be excluded from this study:

    1. Individuals co-infected with other hepatotropic viruses, such as hepatitis A, C, D, or E viruses, or ;
    2. Patients with concomitant liver metabolic disorders, cirrhosis, -related diseases, or other chronic conditions;
    3. Pregnant or breastfeeding women, or those planning pregnancy within one year;
    4. Patients who have received or are currently undergoing antineoplastic therapy;
    5. History of alcohol or substance abuse;
    6. Patients currently taking therapeutic medications or health supplements;
    7. Patients who participated in other clinical trials within 30 days prior to enrolment;
    8. Patients with allergic constitutions or to any drug or component used in this study;
    9. Patients with gastrointestinal disorders that may impair drug absorption.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    TAF Group

    CHB patients with TAF treatment

    Drug: TAF

  • Experimental
    Azvudine Group

    CHB patients with Azvudine treatment

    Drug: AZVUDINE

  • Active comparator
    IFN α-2a Group

    CHB patients with IFN α-2a treatment

    Drug: IFNα-2a

Interventions

06

What researchers measure

Primary outcomes

  1. Follow-up at 12 months

    Taking the medication orally for 12 months.

    Time frame: 12 month

Secondary outcomes

  1. Adverse events

    Discontinuation of medication due to adverse events or other reasons

    Time frame: Up to 30 days (form the date of confirmed CHB)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 29, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07307586
Lead sponsor
Zhigang Ren
Responsible party
Zhigang Ren (The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Zhengzhou University) — Sponsor-investigator
First posted
Dec 29, 2025
Start date
Sep 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Zhigang Ren, Dr.
Contact
fccrenzg@zzu.edu.cn
+8618703636245

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azvudine

Start the discussion